Table 1 The basic demographic and disease characteristics
From: The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
TACE + Sorafenib | TACE | P | ||
|---|---|---|---|---|
(n = 45) | (n = 45) | |||
Age | 51 ± 11.7 | 49 ± 11.0 | >0.05 | |
Men/women | 41/4 | 41/4 | >0.05 | |
PVT | 20 | 23 | >0.05 | |
Distant metastasis | 11 | 12 | >0.05 | |
Prior surgery | 19 | 14 | >0.05 | |
ECOG | >0.05 | |||
0 | 43 | 41 | ||
1 | 2 | 4 | ||
Child pugh | >0.05 | |||
A | 33 | 35 | ||
B | 12 | 10 | ||
C | 0 | 0 | ||
AFP | >0.05 | |||
<400 ng/ml | 16 | 19 | ||
≥400 ng/ml | 29 | 26 | ||
Diagnosis of Hepatitis | >0.05 | |||
HBV | 38 | 37 | ||
HCV | 0 | 0 | ||
None | 7 | 8 | ||
Tumor size, n (%) | ||||
>5 cm | ||||
35(77.78) | 36(80.00) | |||
≤5 cm | ||||
10(22.22) | 9(20.00) | |||
Tumor type, n (%) | >0.05 | |||
Massive | ||||
13(28.89) | 10(22.22) | |||
Multifocal | ||||
16(35.56) | 18(40.00) | |||
Diffuse | ||||
16(35.56) | 17(37.78) | |||
BCLC stage | >0.05 | |||
A | 0 | 0 | ||
B | 16 | 17 | ||
C | 29 | 28 | ||